The Alpha Journal — Men’s Health Reporting

Short-acting injectable testosterone (primarily testosterone cypionate and enanthate) is the most common TRT method in 2025, delivered via intramuscular or subcutaneous injection every 1-2 weeks. While topical gels remain popular, injectables have become the dominant modality in routine U.S. clinical practice due to their efficacy, cost-effectiveness, and patient preference.

TRT typically does not cause erectile dysfunction (ED) when properly administered to hypogonadal men; it usually improves erectile function. However, improper use, particularly supraphysiological dosing or non-medical testosterone use, can suppress natural testosterone production and potentially worsen ED.

TRT may help with weight loss in men with testosterone deficiency by improving body composition, muscle mass, and metabolic health, but results vary between individuals and require medical supervision.

TRT is generally considered safe for long-term use in men with diagnosed hypogonadism when properly monitored, though it requires ongoing medical supervision and individualized dosing to manage potential risks.